PROs Support Switching to Camizestrant Plus CDK4/6 Inhibitor for HR-positive, HER2-negative ABC and Emergent ESR1 Mutations During First-Line Endocrine-Based Therapy By Ogkologos - November 10, 2025 199 0 Facebook Twitter Google+ Pinterest WhatsApp Patient-reported outcomes from the SERENA-6 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Man Offers Free Lawn Mowing Service To Elderly And Veterans August 28, 2021 What to Know About 3 Common Misconceptions Around Food and Cancer... April 25, 2023 Uveal Melanoma: ESMO–EURACAN Clinical Practice Guideline April 2, 2026 Cómo aprendí a sobrellevar la culpa del superviviente después del cáncer May 4, 2022 Load more HOT NEWS Answers to Your Questions About the COVID-19 Vaccine FDA Approves Amivantamab and Hyaluronidase-lpuj for Subcutaneous Injection Thinking outside the box to tackle an aggressive children’s cancer EMA Recommends Granting Marketing Authorisation for Generic Abiraterone Acetate
